

- $\beta$  thalassemia minor, 637, 2242  
 $\beta$  thalassemia trait, 637  
 diagnosis and management of, 638  
 differential diagnosis of, 628, 628t  
 epidemiology of, 633  
 genetic considerations in, 633  
 HSCt for, 139e-2, 139e-5, 139e-5t  
 jaundice in, 281  
 malaria resistance and, 633, 1372  
 peripheral blood smear in, 81e-1, 81e-4f  
 prevention of, 638  
 reticulocyte index in, 399  
 silent, 638t  
 splenomegaly in, 411  
 treatment of, 638  
 Thalassemic structural variants, 638–639  
**Thalidomide**  
 action and targets of, 103e-19  
 adverse effects of, 103e-19, 716–717  
   neuropathy, 607, 2687t, 2688  
   in pregnancy, 1128  
 for ankylosing spondylitis, 2173  
 for Behçet's syndrome, 2194  
 for cough in idiopathic pulmonary fibrosis, 1712  
 for erythema nodosum leprosum, 1128  
 for lupus dermatitis, 2134  
 for malignant pheochromocytoma, 2331  
 for multiple myeloma, 103e-19, 716–717  
 for primary myelofibrosis, 676  
 for vascular ectasias, 277  
 Thallium-201, 270e-3, 270e-3t  
 Thallium poisoning, 203, 472e-3, 2688t, 2689  
*THAP1* gene mutations, 2620  
 Thawing, for frostbite, 478e-4, 478e-4t  
 THBR (thyroid hormone binding ratio), 2288  
 THC (tetrahydrocannabinol), 103e-25, 260t, 444e-4, 469e-2  
 Thecoma, of ovary, 594  
 Thelarche, 2379, 2379t  
**Theophylline**  
 adverse effects of, 305, 324, 1677, 1706, 2547t  
 for asthma, 1677, 1677t  
 for COPD, 1706  
 dosage of, 36  
 drug interactions of, 42t, 1677, 1677t  
   carbapenems, 939t  
   ciprofloxacin, 246e-6t  
   fluoroquinolones, 939t  
   PPIs, 1921  
   thiabendazole, 246e-3t, 246e-13  
 metabolism of, 1677, 1677t  
 overdosage/poisoning with, 473e-8t  
 for SA node dysfunction, 1469  
 therapeutic monitoring of, 2766t  
 Therapeutic diet, 95e-5  
 Therapeutic index, 103e-5  
 Therapeutic index/ratio/window, 32, 32f  
 Therapeutic massage, 14e-1t, 14e-3  
 Therapeutic touch, 14e-1t  
 Thermoregulation, 124, 187, 478e-1, 479e-1  
 THF starvation, 641  
**Thiabendazole**  
 action of, 246e-13  
 adverse effects of, 246e-3t  
 drug interactions of, 246e-3t, 246e-13  
 indications for, 246e-3t  
 pharmacology of, 246e-13  
**Thiamine (vitamin B<sub>1</sub>)**, **96e-1**  
 for alcohol-induced acidosis, 64e-9  
 deficiency of. *See* Thiamine (vitamin B<sub>1</sub>) deficiency  
 food sources of, 96e-1  
 functions of, 96e-1, 96e-2f  
 parenteral requirement for, 98e-5t  
 recommended intake of, 95e-2t  
 reference range for, 2766t  
 structure of, 96e-2f  
 supplements. *See* Thiamine (vitamin B<sub>1</sub>) supplements  
 toxicity of, 96e-3  
**Thiamine (vitamin B<sub>1</sub>) deficiency. *See also* Beriberi**  
 acid-base disorders in, 318  
 in alcoholism, 96e-1, 461  
 cardiac manifestations of, 290e-1t, 290e-2  
 clinical features of, 96e-1t, 96e-2–3, 463t, 2690. *See also* Wernicke's disease/encephalopathy  
 delirium in, 169  
 dementia in, 2607  
 diagnosis of, 2690  
 neuropathies in, 2690  
 optic neuropathy in, 203  
 risk factors for, 96e-1–2, 96e-1t  
 treatment of, 96e-3, 2690  
**Thiamine-responsive megaloblastic anemia**, 435e-1t  
**Thiamine (vitamin B<sub>1</sub>) supplements**, 96e-3  
 for alcohol-induced acidosis, 319  
 for alcohol withdrawal, 2727  
 for dysmenorrhea, 338  
**Thiazide diuretics**  
 action of, 332e-4f, 332e-9  
 adverse effects of, 326  
   cutaneous, 349, 353, 379  
   hypercalcemia, 2478  
   hypokalemia, 306  
   hyponatremia, 299, 301  
   phototoxicity, 389t  
   vasculitis, 382, 2193  
 for chronic kidney disease, 1814  
 drug interactions of, 246e-4t, 246e-6t  
 for hyperkalemia, 312  
 for hypertension, 1623  
 for hypoparathyroidism, 2484  
 for nephrogenic diabetes insipidus, 304, 2279  
 for nephrolithiasis, 1870  
 for paramyotonia congenita, 462e-18  
 for pseudohypoadosteronism, 310  
**Thiazolidinediones**  
 action of, 2414t, 2415  
 adverse effects of, 253t, 2392, 2414t  
 contraindications to, 2414t  
 for metabolic syndrome, 2454  
 for NALFD, 2057  
 for type 2 diabetes mellitus, 2414t, 2415, 2416  
**Thick-filament myopathy**, 1784  
**Thienopyridines**, 747–748. *See also* Clopidogrel; Prasugrel; Ticlopidine  
**Thiethylperazine**, 103e-25, 260t  
**Thimerosal**, 345  
**Thin basement membrane disease**, 294, 1835t, 1847  
**6-Thioguanine**, 103e-10t, 103e-14  
**Thiopental**, 2558f  
**Thiopurine S-methyltransferase (TPMT)**, 34t, 39t, 40, 445  
**Thiopurine S-methyltransferase (TPMT) deficiency**, 451  
**Thioridazine**, 64t, 473e-8t, 473e-9t, 2721, 2722t  
**Thiotepa**, 103e-12, 607t  
**Thiothixene**, 2721, 2722t  
**Third disease. *See* Rubella**  
**Third nerve palsy**, 41e-1v, 1785  
**Third spacing**, 298, 462  
**Third window, inner ear**, 219  
**Thirst**  
 activation of, 295  
 defects in regulation of, 2280  
 in elderly, 303  
 mechanism of, 332e-9, 332e-10f, 2275  
**Thogotoviruses**, 1305, 1310t  
**Thomsen's disease**, 462e-18  
**Thoracentesis**, 474, 482e-1v, 1667  
**Thoracic aortic aneurysm**, 1638–1639, 1639f. *See also* Aortic aneurysm  
**Thoracic lavage**, as rewarming strategy, 478e-3  
**Thoracic meningioma**, 2654f  
**Thoracic outlet**, 122  
**Thoracic outlet syndromes**, 123, 1646–1647  
**Thoracic spinal lesions**, 2651  
**Thoracoscopy, medical**, 1668  
**Thoracotomy**, 1669  
**Thoratec LVAD**, 1518  
**Thorium-232**, in radiation bioterrorism, 263e-3t  
**3TC. *See* Lamivudine (3TC)**  
**Three-dimensional printing**, 92e-2, 92e-3v  
**Threonine kinase gene mutations**, 359  
**Threonine metabolism disorders**, 434e-3t  
**Throat swab**, 150e-4t, 232  
**Thrombectomy, percutaneous mechanical. *See also* Percutaneous interventions**  
 for acute limb ischemia, 1646  
 for ischemic stroke, 2561  
 in STEMI, 297e-2, 297e-2f, 297e-2v  
**Thrombin**  
 in fibrin clot formation, 401, 401f, 746f  
 inhibitors to, 732  
 plasma-derived bovine and human, as hemostatic sealants, 740  
 production of, 744  
**Thrombin-activatable fibrinolysis inhibitor (TAFI)**, 744  
**Thrombin generation test**, 407  
**Thrombin time**, 406t, 407, 733f, 733t  
**Thromboangiitis obliterans**, 1645–1646, 1649  
**Thrombocytopenia**, **725**  
 approach to the patient, 726–727, 726f  
 bleeding in, 404  
 chemotherapy-related, 103e-24  
 drug-induced, 727, 727t  
 familial, with propensity to acute AML, 431t  
 heparin-induced. *See* Heparin-induced thrombocytopenia  
 history in, 726–727  
 in HIV infection, 727, 728, 1262  
 infection-induced, 727  
 inherited, 726, 729  
 in leptospirosis, 1142, 1144  
 peripheral blood smear in, 725, 726f  
 physical examination in, 726–727  
 in pregnancy, 49  
 refractory, 669t. *See also* Myelodysplasia  
 in sepsis/septic shock, 1756  
 skin manifestations of, 367  
 in SLE, 2129t, 2131  
 treatment of, 103e-24  
**Thrombocytopenia with absent radii**, 729  
**Thrombocytopenic purpura**  
 autoimmune, 377e-4  
*H. pylori* infection and, 1040  
 immune, 413, 728–729  
 thrombotic. *See* Thrombotic thrombocytopenic purpura (TTP)  
**Thrombocytosis**  
 erythromelalgia in, 1650  
 essential. *See* Essential thrombocytosis (ET)  
 etiology of, 676t, 730  
 paraneoplastic, 612–613, 612t  
**Thromboembolism**, 1646  
**Thromboembolic disease**  
 acute limb ischemia in, 1646  
 in IBD, 1958  
 in myocardial infarction, 1610  
 pulmonary hypertension in, 1659  
 renal, 1629–1630, 1630f  
**Thromboendarterectomy**, 1636, 1645  
**Thrombogenesis**, 745, 746f  
**Thrombolysis in Myocardial Infarction trial. *See* TIMI (Thrombolysis in Myocardial Infarction) trial**  
**Thrombolytic therapy**  
 for acute limb ischemia, 1646  
 for ischemic stroke, 2561–2562, 2562t  
**Thrombomodulin**, 265e-2, 402  
**Thrombophilia**, 407  
**Thrombophlebitis. *See* Venous thromboembolism (VTE)**  
**Thromboplastin**, 405  
**Thrombopoietin**, 89e-3f, 275, 725, 741  
**Thrombopoietin receptor agonists**, 728–729  
**Thrombopoietin therapy**, 103e-24  
**Thrombosis**, **403**  
 approach to the patient, 404–405  
 arterial. *See* Arterial thrombosis  
 in central venous catheter, 98e-6–7  
 dural sinus, 2572  
 endothelium in, 265e-2  
 epidemiology of, 274, 740  
 in heparin-induced thrombocytopenia, 727  
 history in, 404–405